Why is IMMP up?, page-38

A few short term potential SP catalysts;
1. TACTI-002 'new data' Poster presentations at ASCO early June.

2. , Immutep plans to hold a webcast after ASCO to discuss the data and results, as well as to provide
an update on the Company’s business.

3. AIPAC - Phase IIb clinical trial
The Company is on track to report final overall survival (OS) data from this metastatic breast cancer trial in
H2 of calendar year 2021. Note previous advisory was mid-2021. OS continues to improve (imo).
Currently the trial has reached approximately 72% of events, indicating 72% of total
patients with this late-stage cancer had been followed through until death.
Immutep previously reported an improving OS trend from initial data from approximately 60% of events at the San Antonio Breast Cancer
Conference in December 2020. (data/events was actually from September).

4. Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit. Mid July.
Immutep will participate in the digital Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject. Alongside BP - Merck and BMS senior development managers.